Cost-effectiveness protocol for treating adult HIV-infected patients with Kaposi sarcoma in resource-limited settings: a phase III, randomized, open-label, non-inferiority study of paclitaxel and pegylated liposomal doxorubicin
This study (NCT05411237) is registered on ClinicalTrials.gov, sponsored by the Consortium for Advancing the Prevention and Management of Cancer in People with HIV. It was first posted on June 9, 2022, with the latest update on January 29, 2025. The trial was prospectively registered before participant enrollment. Estimated primary completion is December 2027, with full completion in September 2028.
Authors
- Matthew Painschab (ORCID: https://orcid.org/0000-0001-9175-7436)
- John Chapola (ORCID: https://orcid.org/0000-0002-6669-6499)
- Susan E. Krown (ORCID: https://orcid.org/0000-0003-3395-062X)
- S. Kleber
Institutions
- University of North Carolina at Chapel Hill (US)
- Memorial Sloan Kettering Cancer Center (US)
- Department of Health (ZA)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Cost Effectiveness and Resource Allocation
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1186/s12962-025-00677-x
- Primary Topic
- Viral-associated cancers and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00